Sarwal Reuben D, Yazar Wanzin, Titzler Nicholas, Wong Jeremy, Lai Chih-Hung, Chin Christopher, Krieger Danielle, Stoll Jeff, Dias Lourenco Francisco, Sarwal Minnie M, Ghosh Srinka
NephroSant Inc., 1900 Alameda de las Pulgas, San Mateo, CA 94403, USA.
Department of Surgery, University of California, 400 Parnassus Ave, San Francisco, CA 94143, USA.
J Clin Med. 2022 Feb 9;11(4):910. doi: 10.3390/jcm11040910.
Sub-optimal sensitivity and specificity in current allograft monitoring methodologies underscore the need for more accurate and reflexive immunosurveillance to uncover the flux in alloimmunity between allograft health and the onset and progression of rejection. QSant-a urine based multi-analyte diagnostic test-was developed to profile renal transplant health and prognosticate injury, risk of evolution, and resolution of acute rejection. Q-Score-the composite score, across measurements of DNA, protein and metabolic biomarkers in the QSant assay-enables this risk prognostication. The domain of immune quiescence-below a Q-Score threshold of 32-is well established, based on published AUC of 98% for QSant. However, the trajectory of rejection is variable, given that causality is multi-factorial. Injury and subtypes of rejection are captured by the progression of Q-Score. This publication explores the clinical utility of QSant across the alloimmunity gradient of 32-100 for the early diagnosis of allograft injury and rejection.
当前同种异体移植监测方法的敏感性和特异性欠佳，这凸显了需要更准确且能自动反应的免疫监测，以揭示同种异体移植健康状态与排斥反应的发生及进展之间的同种免疫变化情况。QSant是一种基于尿液的多分析物诊断测试，旨在描绘肾移植健康状况并预测损伤、进展风险以及急性排斥反应的消退情况。QSant检测通过对DNA、蛋白质和代谢生物标志物的测量得出综合分数——Q值，从而实现这种风险预测。根据已发表的QSant曲线下面积（AUC）为98%，免疫静止状态（Q值阈值低于32）已得到充分确立。然而，由于因果关系是多因素的，排斥反应的轨迹是可变的。Q值的进展反映了损伤和排斥反应的亚型。本出版物探讨了QSant在32至100的同种免疫梯度范围内对同种异体移植损伤和排斥反应早期诊断的临床应用价值。
